

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EuroEyes International Eye Clinic Limited
德視佳國際眼科有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1846)

VOLUNTARY ANNOUNCEMENT
UPDATE ON IMPACT OF THE CORONAVIRUS DISEASE 2019 (COVID-19)
OUTBREAK ON BUSINESS OPERATIONS

This announcement is made by EuroEyes International Eye Clinic Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the shareholders and potential investors of the Company informed of the impact of the coronavirus disease 2019 (“**COVID-19**”) outbreak on the Group’s business operations.

BUSINESS AND OPERATIONS OF THE GROUP

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that, despite the impact arising from the lingering COVID-19 pandemic worldwide, the total number of eye surgeries performed by the Group during the two months ended 28 February 2022 was 4,401, which exceeded the total number of eye surgeries performed by the Group for the corresponding period in 2021 (being 4,106 eye surgeries), representing an increase of approximately 7.2%.

The number of refractive laser surgeries performed by the Group during the two months ended 28 February 2022 was 2,229, up approximately 14.3% than the corresponding period in 2021 (being 1,950 refractive laser surgeries). The number of lens exchange surgeries was 1,732, up approximately 6.8% than the corresponding period in 2021 (being 1,621 lens exchange surgeries).

BUSINESS AND OPERATIONS IN THE PRC

Multiple waves of Omicron variant outbreaks emerged in China since the beginning of 2022, spreading to some major cities where the Group operates its business, including Shanghai, Shenzhen, Beijing and Hangzhou. These widespread outbreaks resulted in stringent public health measures, including mass testing, regional lockdowns and travel restrictions, which are expected to have manageable impact on the Group’s business operations.

However, the overall business of the Group has been normal in the PRC, and the changes in public health emergencies and public policy in the PRC should have no material impact on the Group.

BUSINESS AND OPERATIONS IN EUROPE

With the normalization of the COVID-19 pandemic, the Group's business in Europe has been merely affected due to the implementation of normalized COVID-19 prevention and control measures taken by the Group. As of the date of this announcement, the Group's business in Germany, Denmark and United Kingdom has not been materially affected by the COVID-19 pandemic.

OPERATION RISK MANAGEMENT

The Group has a far-reaching geographical coverage with operations in Germany, the PRC, Denmark and the United Kingdom. The global footprints diversify the business risks generated from single region, including changes in the public health emergencies or public policies, which equip the Group with a strong risk mitigator and support the sustainable growth of the Group.

As of the date of this announcement, the Directors expect that the changes in public policies will not have any significant adverse impact on the Group's business.

The Group will continue to regularly monitor the development of the COVID-19 pandemic and relevant public policies, and will assess its impact on the operations and financial performance. The Group will take appropriate measures as necessary and make further announcement as and when appropriate.

Shareholders and investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
EuroEyes International Eye Clinic Limited
Dr. Jørn Slot Jørgensen
Chairman and Executive Director

Hong Kong, 15 March 2022

As at the date of this announcement, the board of Directors comprises Dr. Jørn Slot Jørgensen, Dr. Markus Braun, Dr. Ralf-Christian Lerche, Mr. Jannik Jonas Slot Jørgensen as executive Directors; Mr. Marcus Huascar Bracklo as non-executive Director; Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.